228 related articles for article (PubMed ID: 34023742)
41. Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.
Zhang Z; Huang J; Wang G; Jin F; Zheng J; Xiao H; Lei L; Luo J; Chen C
BMC Cancer; 2020 Mar; 20(1):183. PubMed ID: 32131777
[TBL] [Abstract][Full Text] [Related]
42. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
43. Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy.
Wen DW; Li ZX; Chen FP; Lin L; Peng BY; Kou J; Zheng WH; Yang XL; Xu SS; Sun Y; Zhou GQ
Oral Oncol; 2020 Aug; 107():104675. PubMed ID: 32361563
[TBL] [Abstract][Full Text] [Related]
44. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
45. MRI-Based Back Propagation Neural Network Model as a Powerful Tool for Predicting the Response to Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
Liao H; Chen X; Lu S; Jin G; Pei W; Li Y; Wei Y; Huang X; Wang C; Liang X; Bao H; Liu L; Su D
J Magn Reson Imaging; 2022 Aug; 56(2):547-559. PubMed ID: 34970824
[TBL] [Abstract][Full Text] [Related]
46. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
[TBL] [Abstract][Full Text] [Related]
47. A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
Yang K; Tian J; Zhang B; Li M; Xie W; Zou Y; Tan Q; Liu L; Zhu J; Shou A; Li G
Oral Oncol; 2019 Nov; 98():85-91. PubMed ID: 31569054
[TBL] [Abstract][Full Text] [Related]
48. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
[TBL] [Abstract][Full Text] [Related]
49. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
Zhao C; Miao JJ; Hua YJ; Wang L; Han F; Lu LX; Xiao WW; Wu HJ; Zhu MY; Huang SM; Lin CG; Deng XW; Xie CH
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):836-844. PubMed ID: 30954521
[TBL] [Abstract][Full Text] [Related]
50. Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma.
Xiang ZZ; He T; Zeng YY; Liu F; Shao BF; Yang T; Ma JC; Wang XR; Yu ST; Liu L
Cancer Med; 2023 Jan; 12(2):1102-1113. PubMed ID: 35852473
[TBL] [Abstract][Full Text] [Related]
51. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
[TBL] [Abstract][Full Text] [Related]
52. Prognostic and Treatment Guiding Significance of MRI-Based Tumor Burden Features and Nodal Necrosis in Nasopharyngeal Carcinoma.
Chen X; Cao X; Jing B; Xia W; Ke L; Xiang Y; Liu K; Qiang M; Liang C; Li J; Gao M; Li W; Miao J; Liu G; Cai Z; Lv S; Guo X; Li C; Lv X
Front Oncol; 2020; 10():537318. PubMed ID: 33042831
[TBL] [Abstract][Full Text] [Related]
53. MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma.
Pei W; Wang C; Liao H; Chen X; Wei Y; Huang X; Liang X; Bao H; Su D; Jin G
BMC Cancer; 2022 Jul; 22(1):739. PubMed ID: 35794590
[TBL] [Abstract][Full Text] [Related]
54. Plasma protein-based signature predicts distant metastasis and induction chemotherapy benefit in Nasopharyngeal Carcinoma.
Liang Y; Li J; Li Q; Tang L; Chen L; Mao Y; He Q; Yang X; Lei Y; Hong X; Zhao Y; He S; Guo Y; Wang Y; Zhang P; Liu N; Li Y; Ma J
Theranostics; 2020; 10(21):9767-9778. PubMed ID: 32863958
[No Abstract] [Full Text] [Related]
55. Value of early evaluation of treatment response using
Chen YH; Chang KP; Chu SC; Yen TC; Wang LY; Chang JT; Hsu CL; Ng SH; Liu SH; Chan SC
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):650-660. PubMed ID: 30264225
[TBL] [Abstract][Full Text] [Related]
56. Clonal dynamics of tumor-infiltrating T-cell receptor beta-chain repertoires in the peripheral blood in response to concurrent chemoradiotherapy for Epstein-Barr virus-associated nasopharyngeal carcinoma.
Chung YL; Wu ML
Oncoimmunology; 2021; 10(1):1968172. PubMed ID: 34513316
[TBL] [Abstract][Full Text] [Related]
57. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
[TBL] [Abstract][Full Text] [Related]
58. Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?
Jin YN; Cao HJ; Gong XH; Zhang WJ; Marks T; Yao JJ; Xia LP
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2569-2579. PubMed ID: 34618220
[TBL] [Abstract][Full Text] [Related]
59. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755
[TBL] [Abstract][Full Text] [Related]
60. Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation.
Peng L; Yang Y; Guo R; Mao YP; Xu C; Chen YP; Sun Y; Ma J; Tang LL
Cancer Med; 2018 Dec; 7(12):5988-5998. PubMed ID: 30378277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]